Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 80% below its 3-year average of 0.03, near the low end of its 3-year range (0.00–0.10).
As of the fiscal period ended Tuesday, June 30, 2026. 81.64% below its 12-month average of 0.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.03
DEBT TO EQUITY RATIO AVG 3Y
0.03
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-81.64%
CURRENT VS 3Y AVG
-81.88%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 641 covered companies
CURRENT VS SECTOR MEDIAN
-95.61%
vs the sector median at left
MapLight Therapeutics, Inc.
Market Cap
$397.84M
Debt to Equity Ratio
0.01
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
N/A
Market Cap
$409.27M
Debt to Equity Ratio
0.12
TTM Avg
0.11
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$386.05M
Debt to Equity Ratio
0.20
TTM Avg
0.07
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$384.56M
Debt to Equity Ratio
0.55
TTM Avg
0.43
3Y Avg
0.28
5Y Avg
0.21
Market Cap
$411.32M
Debt to Equity Ratio
0.69
TTM Avg
0.39
3Y Avg
0.28
5Y Avg
0.26
Market Cap
$412.14M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $397.84M | 0.01 | 0.03 | 0.03 | N/A |
| REGENXBIO Inc. (RGNX)vs › | $396.61M | 0.96 | 1.43 | 0.83 | 0.60 |
| Carlsmed, Inc. (CARL)vs › | $408.73M | 0.26 | 0.18 | 0.18 | 0.18 |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | 0.12 | 0.11 | 0.11 | 0.11 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $386.05M | 0.20 | 0.07 | 0.11 | 0.11 |
| Orthofix Medical Inc. (OFIX)vs › | $384.56M | 0.55 | 0.43 | 0.28 | 0.21 |
| Myriad Genetics, Inc. (MYGN)vs › | $411.32M | 0.69 | 0.39 | 0.28 | 0.26 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Neurogene Inc. (NGNE)vs › | $415.36M | 0.04 | 0.04 | 0.06 | 0.06 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.59M | 0.54 | N/A | N/A | N/A |
Debt/Equity
0.01
Current Ratio
16.52
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.10 |
| 2025-03-31 | 0.07 |
| 2024-12-31 | 0.06 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.03 |
| 2023-03-31 | 0.00 |
